# Turn Therapeutics Inc.: overview

TTRX · Nasdaq · CIK 2023016 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ttrx.md) · [Financials](/companies/ttrx/financials.md) · [Filings](/companies/ttrx/filings.md) · [Insiders](/companies/ttrx/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

| Line item | Unit | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.03)](/filings/0001213900-25-109586.md) | not reported | [(0.01)](/filings/0001213900-26-054490.md) | [(0.05)](/filings/0001213900-26-088427.md) | [(0.07)](/filings/0001213900-25-109586.md) | not reported | [(0.03)](/filings/0001213900-26-054490.md) | [(0.20)](/filings/0001213900-26-088427.md) |
| Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: |
| Revenue | $ | not reported | not reported |
| Gross margin | % | not reported | not reported |
| Operating margin | % | not reported | not reported |
| Net margin | % | not reported | not reported |
| Diluted EPS | $ per share | [(0.07)](/filings/0001213900-26-037505.md) | [(0.12)](/filings/0001213900-26-037505.md) |
| Free cash flow | $ | not reported | not reported |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ttrx/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [SteelPeak Wealth, LLC](/funds/1801868.md) | 2026-06-30 | $1.8m | 249,456 |  | New +249,456 |
| [IEQ CAPITAL, LLC](/funds/1779789.md) | 2026-06-30 | $1.7m | 227,396 |  | New +227,396 |
| [DDFG, Inc](/funds/1967640.md) | 2026-06-30 | $787.2k | 107,829 |  | Added +37,295 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $542.4k | 74,301 |  | Added +24,851 |
| [Wellington Shields & Co., LLC](/funds/1506073.md) | 2026-06-30 | $479.8k | 65,732 |  | Unchanged |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $442.0k | 60,551 |  | Reduced −9,206 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $281.7k | 38,591 |  | New +38,591 |
| [Bridgewater Advisors Inc.](/funds/1600319.md) | 2026-06-30 | $241.6k | 27,326 |  | New +27,326 |
| [Aaron Wealth Advisors LLC](/funds/1812198.md) | 2026-06-30 | $237.7k | 32,564 |  | New +32,564 |
| [Tamar Securities, LLC](/funds/1703081.md) | 2026-06-30 | $219.0k | 30,000 |  | Unchanged |

## Recent filings

[All 122 filings](/companies/ttrx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-19 | 20:05 ET | [DEF 14A](/filings/0001213900-26-110670.md) | Proxy statement, period 2026-11-30 | 0001213900-26-110670 |
| 2026-10-07 | 23:30 ET | [8-K](/filings/0001213900-26-107329.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-107329 |
| 2026-09-10 | 12:10 ET | [8-K](/filings/0001213900-26-098584.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-098584 |
| 2026-09-09 | 12:10 ET | [8-K](/filings/0001213900-26-098224.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-098224 |
| 2026-08-18 | 12:30 ET | [8-K](/filings/0001213900-26-091002.md) | 3.02 Unregistered sale of equity | 0001213900-26-091002 |
| 2026-08-17 | 20:14 ET | [8-K](/filings/0001213900-26-090766.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-090766 |
| 2026-08-12 | 20:50 ET | [10-Q](/filings/0001213900-26-088427.md) | Quarterly report, period 2026-06-30 | 0001213900-26-088427 |
| 2026-08-12 | 20:40 ET | [8-K](/filings/0001213900-26-088411.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-088411 |
| 2026-07-28 | 12:05 ET | [8-K](/filings/0001213900-26-081996.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-081996 |
| 2026-07-07 | 12:05 ET | [8-K](/filings/0001213900-26-075757.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-075757 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-037505.md), filed Mar 31, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 2023016
- Tickers: TTRX
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.